In vitro evaluation of guar gum as a carrier for colon-specific drug delivery

Prasad, Y. V. Rama; Krishnaiah, Y. S. R.; Satyanarayana, Srinath

doi:10.1016/s0168-3659(97)00181-8

Cited by 182 publications

(104 citation statements)

References 16 publications

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Rat cecal content was collected using a reported method (Prasad et al, 1998). Wistar rats, weighing 200-300 g, were fed 2 mL of pectin aqueous solution (2%, w/v) daily, for seven days, to induce pectinase activity in the colon.…”

Section: Release Studymentioning

confidence: 99%

Anin situcrosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin

Wei

Lü

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

(2015) An insitu crosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin, Drug Delivery, 22:3, 298-305, DOI: 10.3109/10717544.2013 AbstractThe use of pectin for colon-specific drug delivery has been extensively investigated; however, when used alone, pectin is often compromised due to its high solubility. This study explored the feasibility of using an in situ compression-coated crosslinking system, composed of pectin and calcium chloride, for colon-specific drug delivery. A pectin/calcium chloride (P/Ca) coating was compressed onto a core tablet. The colon specificity of the compression-coated tablet was verified by dissolution, pharmacokinetics and scintigraphy with 99m Tc labeling. The in situ pectin and calcium chloride gel slowed the release of indomethacin. The lag time varied between 3 h and 7 h depending on the amount of calcium chloride and the coating weight. Pectinase triggered the release of indomethacin from the compression-coated tablet, which was then accelerated by the calcium chloride in the coating layer. The compression-coated tablet had a prolonged t max and apparent t 1/2 , as well as a decreased C max and AUC 0-t , compared with the core tablet counterpart. Evaluation with g-scintigraphy verified colonspecific delivery of the compression-coated tablet. In conclusion, the P/Ca in situ crosslinking system worked well for colon-specific drug delivery.

show abstract

Section: Release Studymentioning

confidence: 99%

Anin situcrosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin

Wei

Lü

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…-Drug release studies (n = 3) were conducted under conditions mimicking mouth-to-colon transit (14)(15)(16). The dissolution medium consisted of 900 mL 0.1 mol L -1 HCl for 2 h, replaced by 900 mL Sorensen's phosphate buffer, pH 7.4 for 3 h, kept at 37 ± 0.5°C and stirred at 100 rpm, using a USP (17) dissolution apparatus type II (TDT-06Lplus, Electrolab, India).…”

Section: Methodsmentioning

confidence: 99%

Box-Behnken experimental design in the development of pectin-compritol ATO 888 compression coated colon targeted drug delivery of mesalamine

Patel¹,

Patel²,

Shah³

2010

Acta Pharmaceutica

View full text Add to dashboard Cite

A novel oral colon-specific drug delivery system (CDDS) has been developed as one of the site-specific drug delivery systems. This delivery system, by means of combining one or more controlled release mechanisms, hardly releases the drug in the upper part of the gastrointestinal (GI) tract, but rapidly releases drug in the colon following oral administration. The necessity and advantage of CDDS have been recognized and reviewed recently (1-3). Owing to CDDS specifically delivering the drug to the colon, many bene- The aim of this study was to investigate the combined influence of 3 independent variables in the compression coated tablet of mesalamine for ulcerative colitis. A 3--factor, 3-level Box-Behnken design was used to derive a second order polynomial equation and construct contour plots to predict responses. The independent variables selected were: percentage of polymers (pectin and compritol ATO 888) in compression coating (X 1 ), coating mass (X 2 ) and coating force (X 3 ). Fifteen batches were prepared and evaluated for percent of drug released in 5 h (Y 5 ), time required for 50 % mesalamine to dissolve (t 50 ) with rat cecal (RC) content and without rat cecal content (t 50 ), percent of drug released in 24 h in the presence of rat cecal content (Y 24 with RC). Transformed values of independent and dependent variables were subjected to multiple regressions to establish a full-model second-order polynomial equation. F was calculated to confirm the omission of insignificant terms from the full-model equation. The computer optimization process and contour plots predicted the levels of independent variables X 1 , X 2 , and X 3 (0, 0.2 and -0.15, respectively) for colon targeting and total percent of drug released up to 24 h.

show abstract

“…When HPMC concentration in the coat was 5% (F1), drug release continued to be low up to the first hour and half in PB pH 6.8, and then it increased reaching 86.42% ± 1.33 after 5 h. On the other hand, coating containing 10% HPMC showed retarded release in PB pH 6.8 up to 5 h (17.80% ± 2.69). The cumulative % release less than 20% after 5 h has been used as indicative of colon targeting [28,29]. As a result, tablets coated with 10% HPMC together with 90% EUD-L (F2) have been selected to investigate the protection activity of naringin against indomethacin-induced colitis in rabbits.…”

Section: In Vitro Release Studymentioning

confidence: 99%

Colon Targeting of Naringin for Cytoprotection against Ulcerative Colitis: In Vitro-In Vivo Study

Borg¹,

Mohamed²,

Naggar³

et al. 2017

IOSRJPBS

View full text Add to dashboard Cite

In vitro evaluation of guar gum as a carrier for colon-specific drug delivery

Cited by 182 publications

References 16 publications

Anin situcrosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin

Anin situcrosslinked compression coat comprised of pectin and calcium chloride for colon-specific delivery of indomethacin

Box-Behnken experimental design in the development of pectin-compritol ATO 888 compression coated colon targeted drug delivery of mesalamine

Colon Targeting of Naringin for Cytoprotection against Ulcerative Colitis: In Vitro-In Vivo Study

Contact Info

Product

Resources

About